Trial reportJournal of cardiothoracic surgery2026
Comparison of high-flow nasal cannula oxygen therapy versus nasal cannula in sedated transoesophageal echocardiography in patients with mitral regurgitation: a prospective, randomized controlled clinical trial.
Trial report in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with moderate-to-severe mitral regurgitation (MR) undergoing pre-procedural transesophageal echocardiography (TEE) for transcatheter edge-to-edge repair (TEER) are at high risk for hypoxia during propofol sedation. We evaluated the efficacy and safety of high-flow nasal cannula (HFNC) oxygen therapy compared with conventional nasal cannula in this population.
methodsThis prospective, single-center, randomized controlled trial enrolled 263 patients with moderate-to-severe MR scheduled for pre-procedural TEE under propofol sedation. Patients were randomized to receive either HFNC or conventional nasal cannula. The primary outcome was the incidence of hypoxia. Secondary outcomes included subclinical respiratory depression, need for airway interventions, hemodynamic parameters, adverse events, and satisfaction scores.
resultsHFNC significantly reduced hypoxia incidence compared with conventional oxygen (13.74% vs. 23.48%; relative risk 0.59, 95% CI 0.35–0.99; p = 0.040). HFNC also decreased subclinical respiratory depression (18.32% vs. 32.58%; p = 0.007) and need for jaw-lift maneuvers (20.61% vs. 33.33%; p = 0.026). No patients in the HFNC group required mask ventilation versus 12.88% in the control group (p < 0.001). Operator and anesthesiologist satisfaction scores were higher with HFNC (both p < 0.01). No serious HFNC-related adverse events occurred.
conclusionsHFNC significantly reduces hypoxia and airway interventions during pre-procedural TEE in patients with MR, with improved safety and satisfaction profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.